Global Healthcare Opportunities, or GHO Capital Partners, announced the sale of VISUfarma, a specialty pharmaceutical company focused on ophthalmology, to Lupin Limited.

Financial terms of the deal were not disclosed. 

VISUfarma was formed in 2016 when GHO Capital combined the founder-owned Italian VISUfarma with the European commercial operations of Nicox SA. Under GHO’s ownership, VISUfarma has grown into a pan-European leader with operations in Italy, the United Kingdom, Spain, Germany, and France, supported by a portfolio of more than 60 branded ophthalmology products.

According to GHO Capital partners Andrea Ponti and Mike Turner, VISUfarma has been transformed from a domestic player into a unique European business with a robust product offering across front- and back-of-the-eye disease areas. “We are pleased to have found a partner that can help grow VISUfarma further and leverage its strengths to build a global ophthalmology franchise,” Andrea Ponti said.

The acquisition aligns with Lupin’s strategy to accelerate its European footprint and bolster its global specialty portfolio. Through its wholly owned subsidiary, Nanomi BV, Lupin gains direct access to established markets and a diverse pipeline in ophthalmology, including therapies for dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialized nutraceuticals.

“We are delighted to welcome VISUfarma into the Lupin family. This acquisition strengthens our commitment to delivering innovative medicines to the patients and communities we serve. Beyond being immediately accretive, it also broadens our presence in Europe and further builds our specialty franchise in ophthalmology,” said Vinita Gupta, CEO of Lupin.